
UK Records Near-200 Deaths Linked to GLP-1 Weight-Loss Drugs, Regulator Cautions on Causation
UK MHRA Yellow Card data show roughly 200 deaths linked to GLP-1 obesity drugs (about 59 with semaglutide Ozempic/Wegovy, 120 with tirzepatide Mounjaro, 37 with liraglutide Saxenda) and over 150,000 adverse reactions. The regulator notes that reportings do not prove causation and many deaths may be due to underlying illnesses, while emphasizing GLP-1 medicines are safe for the majority of users; examples in investigations include deaths of Caroline Savage and Paula Owen.













